Iovance Biotherapeutics, Inc. (IOVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IOVA Stock Price Chart Interactive Chart >
IOVA Price/Volume Stats
| Current price | $7.02 | 52-week high | $28.00 |
| Prev. close | $15.12 | 52-week low | $6.75 |
| Day low | $6.75 | Volume | 36,758,801 |
| Day high | $7.91 | Avg. volume | 2,501,119 |
| 50-day MA | $15.69 | Dividend yield | N/A |
| 200-day MA | $18.92 | Market Cap | 1.10B |
Iovance Biotherapeutics, Inc. (IOVA) Company Bio
Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.
Latest IOVA News From Around the Web
Below are the latest news stories about Iovance Biotherapeutics Inc that investors may wish to consider to help them evaluate IOVA as an investment opportunity.
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdatesExpanding TIL Platform in Multiple Solid Tumors and Treatment SettingsSAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported fourth quarter and full year 2021 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer o |
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. |
AlloVir: A Comparative Study Of Its Manufacturing ProcessI covered AlloVir (ALVR) early last year, and like so many things in 2021, the stock hasn’t done well. AlloVir is Marker’s (MRKR) sister company, and uses the same technology in infectious diseases instead of Marker’s cancer focus. A number of other companies - SQZ Biotechnologies (SQZ), Iovance (IOVA), and... |
Did The Smart Money Get Iovance Biotherapeutics, Inc. (IOVA) Right?Technology stocks had a lousy start to 2022. QQQ lost 9% of its value in January. Pandemic winners are getting crushed while energy stocks are surging. |
Carnegie Capital Asset Management, LLC Buys Coinbase Global Inc, GXO Logistics Inc, Upstart ...Beachwood, OH, based Investment company Carnegie Capital Asset Management, LLC (Current Portfolio) buys Coinbase Global Inc, GXO Logistics Inc, Upstart Holdings Inc, FuboTV Inc, QuantumScape Corp, sells , Guardant Health Inc, Verizon Communications Inc, Arista Networks Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Carnegie Capital Asset Management, LLC. |
IOVA Price Returns
| 1-mo | -53.66% |
| 3-mo | -55.20% |
| 6-mo | -62.50% |
| 1-year | -62.20% |
| 3-year | -60.63% |
| 5-year | 36.31% |
| YTD | -63.23% |
| 2021 | -58.86% |
| 2020 | 67.63% |
| 2019 | 212.77% |
| 2018 | 10.63% |
| 2017 | 15.11% |
Loading social stream, please wait...